Percutaneous closure of patent foramen ovale: "Closed" door after the last randomized trials?

In conclusion, our interpretation of these trials is that the use of a dedicated, specifically designed Amplatzer PFO device could possibly reduce the risk of stroke in patients with PFO and cryptogenic stroke. This consideration equally applies to patients who have no contraindications for anticoagulant or antithrombotic therapy. PMID: 24527181 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/24527181?dopt=Abstract

Source: World Journal of Cardiology - January 26, 2014 Category: Cardiology Authors: Hernandez J, Moreno R Tags: World J Cardiol Source Type: research